摘要
目的:探讨上皮性卵巢癌组织中ATF5(activating transcription faclor 5,ATF5)基因的表达及其临床意义。方法:采用免疫组织化学染色法和逆转录酶聚合酶链反应(riverse transcription polymerase chain reaction,RT-PCR)方法从蛋白和mRNA水平检测60例上皮性卵巢癌组织、15例良性卵巢肿瘤和9例正常卵巢组织标本中ATF5的表达差异。结果:上皮性卵巢癌组织中ATF5阳性表达率显著高于正常卵巢及卵巢良性肿瘤组织(P<0.05),且ATF5蛋白和mRNA表达强度与上皮性卵巢癌手术病理分期和组织分化程度有关。Ⅲ～Ⅳ期的阳性表达率及表达强度明显高于Ⅰ～Ⅱ期(P<0.05);低分化组高于中分化及高分化组(P<0.05),但中分化及高分化组之间ATF5表达无显著性差异(P>0.05)。结论:ATF5在上皮性卵巢癌组织中呈高表达,其表达强度与临床分期和组织分化程度密切相关,为卵巢癌的治疗提供新的靶点。
Objective： This work aims to investigate the expression and significance of activating transcription factor 5 （ ATF5 ） in epithelial ovarian carcinoma. Methods： Reverse transcription polymerase chain reaction was used to determine ATF5 mRNA expression. The immunohistochemical staining method was employed to assay the expression of ATF5 protein in the specimens of 60 cases with epithelial ovarian carcinoma, 15 cases of benign ovarian tumor, and 9 cases of normal ovarian tissue. Results： ATF5 expression was significantly higher in epithelial ovarian carcinoma than in benign ovarian tumor and normal controls （ P 〈 0.05 ）. The over-expression of ATF5 was related to the differentiation and clinical stage. The positive rates of ATF5 were notably higher in stages III-IV carcinoma than in stages I-II （ P 〈 0.05 ）. The positive rates of ATF5 were also higher in the poor differentiation group than in the good and moderate differentiation group. However, no significant differences were found between the groups with cancers of good and moderate differentiations （ P 〉 0.05 ）. Conclusion： ATF5 is over-expressed in epithelial ovarian carcinoma. The level of ATF5 expression is related to differentiation and clinical staging. The findings may serve as a foundation for further studies on the correlation between ATF5 and oncogenesis of ovarian cancer, and on the role of ATF5 in biological behaviors of ovarian carcinoma.
出处
《中国肿瘤临床》
CAS
CSCD
北大核心
2012年第4期205-207,211,共4页
Chinese Journal of Clinical Oncology
关键词
上皮性卵巢癌转录激活因子5逆转录酶聚合酶链反应免疫组化
Epithelial ovarian carcinoma
Activating transcription factor 5
Reverse transcription polymerase chain reaction
Im-munohistochemistry
